New final guidance from the US Food and Drug Administration lays out how the agency plans to approach the recognition and withdrawal of voluntary consensus standards that can be used to support regulatory submissions.
The guidance document, which was issued on 15 September, finalizes a draft guidance issued in 2018.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?